GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ARWR · Jun 30, 2026

ARROWHEAD PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000879407-26-000057General Corporate

Capex intensity50thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

5.12% · OPTIONAL · VALID

Operating cash generation50thOwn-history percentile · N=8

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-235.83% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

171.02% · CORE · NOT_ENOUGH_HISTORY

Operating margin50thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.operating_margin

-226.03% · CORE · VALID

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

263.41% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensity38thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

19.90% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History5 statesHistory building

Dec 31, 20240/5 normalizedLevel 3 Sep 30, 20250/6 normalizedLevel 3 Dec 31, 20250/6 normalizedLevel 3 Mar 31, 20260/6 normalizedLevel 3 Jun 30, 20264/6 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 3.48%
Current: 5.12%
Delta: 1.64%

Cash Generation Decreased

Previous: 114.52%
Current: -235.83%
Delta: -350.35%

Growth Increased

Previous: -86.41%
Current: 171.02%
Delta: 257.43%

Profitability Decreased

Previous: -191.57%
Current: -226.03%
Delta: -34.46%

R And D Intensity Increased

Previous: 234.96%
Current: 263.41%
Delta: 28.45%

Sbc Intensity Decreased

Previous: 22.47%
Current: 19.90%
Delta: -2.57%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Has State · ARROWHEAD PHARMACEUTICALS, INC. →Transitioned To · ARWR Fundamental State →Transitioned To · ARWR CAPEX_INTENSITY_INCREASED →Transitioned To · ARWR CASH_GENERATION_DECREASED →Transitioned To · ARWR GROWTH_INCREASED →Transitioned To · ARWR PROFITABILITY_DECREASED →Transitioned To · ARWR R_AND_D_INTENSITY_INCREASED →Transitioned To · ARWR SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.